Work

Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps9603

Authors: Siwen Hu-Lieskovan, James Moon, Danae Campos, Kenneth F. Grossmann, Jeffrey Alan Sosman, Christopher W. Ryan, Michael Wu, Antoni Ribas

Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, SWOG Cancer Research Network, Moffitt Cancer Center, Northwestern University, Northwestern Medicine, Oregon Health & Science University, OHSU Knight Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890653531

Cites:

Cited by: 8

Related to: 10